122 related articles for article (PubMed ID: 19744012)
1. Effect of CYP3A5*3 genotype on serum carbamazepine concentrations at steady-state in Korean epileptic patients.
Park PW; Seo YH; Ahn JY; Kim KA; Park JY
J Clin Pharm Ther; 2009 Oct; 34(5):569-74. PubMed ID: 19744012
[TBL] [Abstract][Full Text] [Related]
2. Effects of CYP3A5 and UGT2B7 variants on steady-state carbamazepine concentrations in Chinese epileptic patients.
Lu Q; Huang YT; Shu Y; Xu P; Xiang DX; Qu Q; Qu J
Medicine (Baltimore); 2018 Jul; 97(30):e11662. PubMed ID: 30045320
[TBL] [Abstract][Full Text] [Related]
3. Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on dose-adjusted plasma levels of carbamazepine in epileptic patients in South Indian population.
Ganesapandian M; Ramasamy K; Adithan S; Narayan SK
Indian J Pharmacol; 2019; 51(6):384-388. PubMed ID: 32029960
[TBL] [Abstract][Full Text] [Related]
4. Effects of CYP3A4/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy.
Wang P; Yin T; Ma HY; Liu DQ; Sheng YH; Wang C; Zhou BT
Epilepsy Res; 2015 Nov; 117():52-7. PubMed ID: 26421491
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of steady-state carbamazepine in Egyptian epilepsy patients.
El Desoky ES; Sabarinath SN; Hamdi MM; Bewernitz M; Derendorf H
J Clin Pharm Ther; 2012 Jun; 37(3):352-5. PubMed ID: 21883329
[TBL] [Abstract][Full Text] [Related]
6. Associations between CYP3A4, CYP3A5 and SCN1A polymorphisms and carbamazepine metabolism in epilepsy: A meta-analysis.
Zhao GX; Zhang Z; Cai WK; Shen ML; Wang P; He GH
Epilepsy Res; 2021 Jul; 173():106615. PubMed ID: 33756436
[TBL] [Abstract][Full Text] [Related]
7. Effects of major transporter and metabolizing enzyme gene polymorphisms on carbamazepine metabolism in Chinese patients with epilepsy.
Zhu X; Yun W; Sun X; Qiu F; Zhao L; Guo Y
Pharmacogenomics; 2014; 15(15):1867-79. PubMed ID: 25495409
[TBL] [Abstract][Full Text] [Related]
8. Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients.
Ragueneau-Majlessi I; Levy RH; Bergen D; Garnett W; Rosenfeld W; Mather G; Shah J; Grundy JS
Epilepsy Res; 2004 Nov; 62(1):1-11. PubMed ID: 15519127
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetic modelling of carbamazepine in epileptic elderly patients: implications for dosage.
Bondareva IB; Jelliffe RW; Gusev EI; Guekht AB; Melikyan EG; Belousov YB
J Clin Pharm Ther; 2006 Jun; 31(3):211-21. PubMed ID: 16789986
[TBL] [Abstract][Full Text] [Related]
10. Effect of cytochrome P450 3A5*3 genotype on the stereoselective pharmacokinetics of amlodipine in healthy subjects.
Kim KA; Park PW; Park JY
Chirality; 2009 May; 21(5):485-91. PubMed ID: 18752284
[TBL] [Abstract][Full Text] [Related]
11. Effects of EPHX1 and CYP3A4*22 genetic polymorphisms on carbamazepine metabolism and drug response among Tunisian epileptic patients.
Chbili C; Fathallah N; Laouani A; Nouira M; Hassine A; Ben Amor S; Ben Ammou S; Ben Salem C; Saguem S
J Neurogenet; 2016 Mar; 30(1):16-21. PubMed ID: 27276192
[TBL] [Abstract][Full Text] [Related]
12. Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy.
Puranik YG; Birnbaum AK; Marino SE; Ahmed G; Cloyd JC; Remmel RP; Leppik IE; Lamba JK
Pharmacogenomics; 2013 Jan; 14(1):35-45. PubMed ID: 23252947
[TBL] [Abstract][Full Text] [Related]
13. Effect of CYP3A5 genotypes on the pharmacokinetics of carbamazepine when used as monotherapy or co-administered with phenytoin, phenobarbital or valproic acid in Thai patients.
Panomvana D; Traiyawong T; Towanabut S
J Pharm Pharm Sci; 2013; 16(4):502-10. PubMed ID: 24210059
[TBL] [Abstract][Full Text] [Related]
14. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects.
Kim KA; Park PW; Lee OJ; Choi SH; Min BH; Shin KH; Chun BG; Shin JG; Park JY
Clin Pharmacol Ther; 2006 Dec; 80(6):646-56. PubMed ID: 17178265
[TBL] [Abstract][Full Text] [Related]
15. [The clinical relevance of serial determinations of plasma concentrations of carbamazepine and sodium valproate].
Hernández-Fustes OJ; Marcourakis T; de Bittencourt PR
Rev Neurol; 1999 Jun 1-15; 28(11):1043-7. PubMed ID: 10390769
[TBL] [Abstract][Full Text] [Related]
16. Carbamazepine 10,11-epoxidation in human liver microsomes: influence of the
Miyata-Nozaka Y; Zain SM; Taguchi M; Shigeyama M; Isobe T; Hanioka N
Pharmazie; 2017 Dec; 72(12):747-750. PubMed ID: 29441960
[TBL] [Abstract][Full Text] [Related]
17. Association of MDR1 (C3435T) polymorphism and resistance to carbamazepine in epileptic patients from Turkey.
Ozgon GO; Bebek N; Gul G; Cine N
Eur Neurol; 2008; 59(1-2):67-70. PubMed ID: 17917461
[TBL] [Abstract][Full Text] [Related]
18. Association of drug levels & pharmacokinetics of carbamazepine with seizure control.
Vasudev A; Tripathi KD; Puri V
Indian J Med Res; 2000 Dec; 112():218-23. PubMed ID: 11247200
[TBL] [Abstract][Full Text] [Related]
19. Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients.
Kang RH; Jung SM; Kim KA; Lee DK; Cho HK; Jung BJ; Kim YK; Kim SH; Han C; Lee MS; Park JY
J Clin Psychopharmacol; 2009 Jun; 29(3):272-7. PubMed ID: 19440082
[TBL] [Abstract][Full Text] [Related]
20. Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects.
Kim KA; Park PW; Lee OJ; Kang DK; Park JY
J Clin Pharmacol; 2007 Jan; 47(1):87-93. PubMed ID: 17192506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
